ShangBay Capital’s William Dai Recognized Among GrowthCap’s Top 25 Healthcare Investors for 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--ShangBay Capital, a prominent venture capital firm specializing in healthcare investments, proudly announces the inclusion of William Dai in GrowthCap's esteemed list of top healthcare investors for 2025.

This prestigious accolade marks William Dai’s third year being recognized as one of GrowthCap’s Top 25 Healthcare Investors. His exceptional contributions to the healthcare sector, alongside a distinguished cohort of industry leaders, highlight his position as one of the foremost investors in the field. The selection process focused on investment expertise, track record, impact on the healthcare landscape, and support for portfolio company growth.

William Dai, Founding Managing Partner at ShangBay Capital, spearheads the firm's healthcare investment initiatives, with a particular emphasis on medtech ventures. Since its inception in 2015, ShangBay Capital, under William's leadership, has emerged as a successful venture capital entity, nurturing 72 portfolio companies and achieving multiple successful exits. ShangBay's investment portfolio includes Ceribell, an AI-enabled EEG system that has become one of the best Medtech IPOs in recent years, and where ShangBay was the first institutional investor. Additionally, ShangBay has syndicated 26 portfolio companies with major strategics. Currently, William serves on the boards of directors for Luminopia, Aqua Medical, Meditrina, FemDx, and YorLabs. He has also previously served on the boards of NeuroVasc (acquired in 2019) and Arrinex (acquired by Stryker in 2019). As the Founding Managing Partner at ShangBay Capital, he has played a critical role in leading and executing investment transactions to drive business success.

With over two decades of experience in corporate finance, mergers and acquisitions, and capital markets across Asia and the U.S., William Dai brings a wealth of expertise to the healthcare investment realm. Prior to founding ShangBay Capital, he held CFO positions at ShangPharma (NYSE: SHP), Nepstar Corporation (NYSE: NPD), Microport Scientific Corporation (HK: 00853), and Boston Scientific China, where he played pivotal roles in driving business transactions and fostering organizational success.

“This past year has underscored the profound impact that medical technology can have on improving patient outcomes. I feel privileged to contribute to this dynamic and meaningful field, working alongside innovators who are redefining what’s possible in healthcare. As we look ahead, I remain committed to supporting the next generation of pioneering medtech companies,” remarked William Dai.